Posted: 10 December 2024 The Australian Research Council (ARC) today announced more than $342 million in funding for 536 new projects under the 2025 ARC Discovery Projects scheme. ARC Acting Chief Executive Officer, Dr Richard Johnson, said the…
Posted: 10 December 2024 Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that it has received firm commitments for a placement of 44,444,445 new,…
Posted: 5 December 2024 AGRF (Australian Genome Research Facility Ltd) and Integrated Sciences are excited to announce a new partnership that will bring advanced genomics capabilities to researchers across Australia and New Zealand. This collaboration will enable AGRF’s…
Posted: 5 December 2024 INOVIQ Limited (ASX:IIQ or INOVIQ) is pleased to announce the successful completion of disease specificity testing for breast cancer. The INOVIQ blood test is a simple, accurate and affordable immunoassay developed using a monoclonal…
Posted: 4 December 2024 Telix and Grand Pharma today announce that a first patient has been dosed in the Phase III ZIRCON-CP trial of TLX250-CDx positron emission tomography (PET) imaging of clear cell renal cell carcinoma (ccRCC). The…
Posted: 4 December 2024 INOVIQ Limited (ASX:IIQ or INOVIQ) is pleased to announce that its blood test for ovarian cancer screening has successfully completed an independent patient validation of its biomarkers and diagnostic performance, delivering outstanding test results…
Posted: 4 December 2024 Before her death from cancer in August his year, Dr Depaz was Country Medical Lead and Head of Medical Vaccines for Sanofi Australia & New Zealand, as well as Managing Director of the Translational…
Posted: 4 December 2024 The exceptional research, discovery and advocacy legacy of former WEHI director and Australian treasure Sir Gustav Nossal AC CBE will continue through an ongoing professorship, announced today by WEHI and the Nossal family. Launched with a…
Posted: 4 December 2024 Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that the last patient in the ATH434-201 Phase 2 trial,…
Posted: 27 November 2024 Optiscan has been featured in Stockhead and The Australian regarding its partnership with the University of Minnesota to advance cancer detection in pets. This collaboration focuses on utilizing Optiscan’s confocal endomicroscope imaging system to…
Posted: 27 November 2024 A promising daily tablet is effective at increasing height and improving proportional limb growth in children with achondroplasia, the most common form of dwarfism, according to a new study. And the findings could spare…
Posted: 27 November 2024 Moderna, Inc (NASDAQ: MRNA), today announced the awardees of its 2024 Australia Fellowship Program. The program, in its second year, is dedicated to developing the country’s world-leading health and medical research sector in mRNA…